Comparison of Pretreatment Characteristics of Patients With AML With t(8; 21) With and Without CD56 Expression
| . | CD56+ . | CD56− . | P Value . |
|---|---|---|---|
| . | (n = 16) . | (n = 13) . | . |
| Median age (y) | 38 | 37 | 1.0 |
| Sex (% female) | 38 | 31 | 1.0 |
| Granulocytic sarcoma (%) | 13 | 0 | .49 |
| White blood cell count >10 × 109/L (%) | 63 | 54 | .72 |
| Median absolute granulocyte count (×109/L) | 3.4 | 4.2 | .35 |
| Additional cytogenetic abnormalities (%) | 75 | 69 | 1.0 |
| Loss of X or Y chromosome (%) | 56 | 54 | 1.0 |
| del(9q) (%) | 13 | 23 | .63 |
| . | CD56+ . | CD56− . | P Value . |
|---|---|---|---|
| . | (n = 16) . | (n = 13) . | . |
| Median age (y) | 38 | 37 | 1.0 |
| Sex (% female) | 38 | 31 | 1.0 |
| Granulocytic sarcoma (%) | 13 | 0 | .49 |
| White blood cell count >10 × 109/L (%) | 63 | 54 | .72 |
| Median absolute granulocyte count (×109/L) | 3.4 | 4.2 | .35 |
| Additional cytogenetic abnormalities (%) | 75 | 69 | 1.0 |
| Loss of X or Y chromosome (%) | 56 | 54 | 1.0 |
| del(9q) (%) | 13 | 23 | .63 |